Lovisa Afzelius, Flagship Pioneering ๐ธ๐ช | Company building, AI | E24
Description
In our first episode recorded live in front of an audience, weโre with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering ๐ธ๐ช
We talk about Flagship, including its EU activities. We also talk about company-building and Lovisaโs personal journey to be one of the leading Swedish leaders in biotech.
โญ๏ธ ABOUT THE SPEAKER
Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines. Lovisa has received many accolades. A few include being listed on Inc. Magazineโs Female Founders 250 List in 2024, 2023 she featured in the PharmaVoice 100 list of life science industry leaders.
๐ย LINKS MENTIONED
- Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial: https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app
- Agnete Fredriksen, Nykode | Being one of the top 50 women in ๐ช๐บ Bio | E07: https://flot.bio/episode/agnete-fredriksen-top-women-bio/
- BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024: https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and
- Nouscom Raises โฌ67.5 Million ($72 Million) In Oversubscribed Series C Financing Round: https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/
- Otello Stampacchia, Omega Funds ๐ฎ๐น | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/
๐ TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/
๐ธย DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
โญ๏ธ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
๐ซถ FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio
๐ LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
๐๏ธ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
โฐ TIMESTAMPS
[00:00:00 ] Intro
[00:02:08 ] Flagship Pioneering and their EU biotech initiatives
[00:06:18 ] Being creative in many biotech spheres
[00:08:37 ] Why invest 50m in first seed Series A every time?
[00:11:42 ] The Flagship Pioneering business model: invest early
[00:15:57 ] VC-created vs founder-led biotechs
[00:17:46 ] Raising one of the largest biotech funds
[00:19:19 ] Flagship Pioneeringโs biggest returns
[00:22:36 ] AI & biotech
[00:26:31 ] What does success mean to Flagship Pioneering
[00:29:20 ] How to help biotech spinoffs grow and advice for women to be biotech leaders
[00:34:03 ] How to move from computational to translation sciences & bring drugs to market faster
[00:37:14 ] What can the EU learn from the US to create biotechs
[00:40:36 ] How do you bridge the gap between biotech company creation in the US vs EU
[00:43:07 ] Lessons for an early-stage biotech career
[00:47:18 ] How to attract the best biotech talent
[00:48:38 ] Moving to Boston
[00:52:13 ] Quickfire
[00:55:41 ] Thanks for listening